Abstract
It has been estimated that the cost of bringing a new drug onto the market is 10 years and 0.5-2 billions of dollars, making it a non-profitable project, particularly in the case of low prevalence diseases. The advances in Systems Biology have been absolutely decisive for drug discovery, as iterative rounds of predictions made from in silico models followed by selected experimental validations have resulted in a substantial saving of time and investments. Many diseases have their origins in proteins that are not located in the cytosol but in intracellular compartments (i.e. mitochondria, lysosome, peroxisome and others) or cell membranes. In these cases, biocomputational approaches present limitations to their study. In the present work, we review them and propose new initiatives to advance towards a safer, more efficient and personalized pharmacology. This focus could be especially useful for drug discovery and the reposition of known drugs in rare and emergent diseases associated with compartmentalized proteins.
Keywords: Systems biology, diseasomes, compartmentalized proteins, drug discovery, rare diseases, lysosome, mitochondria, peroxisome.
Current Pharmaceutical Design
Title:Biocomputational Resources Useful For Drug Discovery Against Compartmentalized Targets
Volume: 20 Issue: 2
Author(s): Francisca Sanchez-Jimenez, Armando Reyes-Palomares, Aurelio A. Moya-Garcia, Juan AG Ranea and Miguel Angel Medina
Affiliation:
Keywords: Systems biology, diseasomes, compartmentalized proteins, drug discovery, rare diseases, lysosome, mitochondria, peroxisome.
Abstract: It has been estimated that the cost of bringing a new drug onto the market is 10 years and 0.5-2 billions of dollars, making it a non-profitable project, particularly in the case of low prevalence diseases. The advances in Systems Biology have been absolutely decisive for drug discovery, as iterative rounds of predictions made from in silico models followed by selected experimental validations have resulted in a substantial saving of time and investments. Many diseases have their origins in proteins that are not located in the cytosol but in intracellular compartments (i.e. mitochondria, lysosome, peroxisome and others) or cell membranes. In these cases, biocomputational approaches present limitations to their study. In the present work, we review them and propose new initiatives to advance towards a safer, more efficient and personalized pharmacology. This focus could be especially useful for drug discovery and the reposition of known drugs in rare and emergent diseases associated with compartmentalized proteins.
Export Options
About this article
Cite this article as:
Sanchez-Jimenez Francisca, Reyes-Palomares Armando, Moya-Garcia A. Aurelio, Ranea AG Juan and Medina Angel Miguel, Biocomputational Resources Useful For Drug Discovery Against Compartmentalized Targets, Current Pharmaceutical Design 2014; 20 (2) . https://dx.doi.org/10.2174/13816128113199990030
DOI https://dx.doi.org/10.2174/13816128113199990030 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Formulation and In Vitro Evaluation of Gelatin Nanospheres for the Oral Delivery of Selegiline
Current Nanoscience The Current View on the Helicase Activity of RNA Helicase A and Its Role in Gene Expression
Current Protein & Peptide Science The Application of Mass Spectrometry to Proteomics and Metabolomics in Biomarker Discovery and Drug Development
Current Molecular Pharmacology Cell Based-Gene Delivery Approaches for the Treatment of Spinal Cord Injury and Neurodegenerative Disorders
Current Stem Cell Research & Therapy Deciphering the Role of Aberrant Protein Post-Translational Modification in the Pathology of Neurodegeneration
CNS & Neurological Disorders - Drug Targets Cross-Talk Between NO Synthase Isoforms in Neuro-Inflammation: Possible Implications in HIV-Associated Neurocognitive Disorders
Current Medicinal Chemistry Neurodegenerative Diseases: New Hopes and Perspectives
Current Molecular Medicine An Enriched Population of CD45, CD34 and CD117 Stem Cells in Human Umbilical Cord Blood for Potential Therapeutic Regenerative Strategies
Current Neurovascular Research Editorial (Hot Topic: Network Biology: Towards Systematic Understanding of Biological Systems)
Current Bioinformatics The Mitochondriotropic Effects of L-carnitine and its Esters in the Central Nervous System
Current Medicinal Chemistry - Central Nervous System Agents TNF α Signaling Beholds Thalidomide Saga: A Review of Mechanistic Role of TNF-α Signaling Under Thalidomide
Current Topics in Medicinal Chemistry Nutrition, Immunity and Aging: Current Scenario and Future Perspectives in Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets The Immunoproteasome: An Emerging Therapeutic Target
Current Topics in Medicinal Chemistry Role of Histone Deacetylases (HDACs) in Epilepsy and Epileptogenesis
Current Pharmaceutical Design Recent Advancement of Pyrazole Scaffold Based Neuroprotective Agents: A Review
CNS & Neurological Disorders - Drug Targets The Role of Mitochondrial Genes in Neurodegenerative Disorders
Current Neuropharmacology Patients with Increased Non-Ceruloplasmin Copper Appear a Distinct Sub-Group of Alzheimer's Disease: A Neuroimaging Study
Current Alzheimer Research The Dopaminergic System in Peripheral Blood Lymphocytes: From Physiology to Pharmacology and Potential Applications to Neuropsychiatric Disorders
Current Neuropharmacology Metabotropic Purinergic Receptors in Lipid Membrane Microdomains
Current Medicinal Chemistry Role of Hexokinase and VDAC in Neurological Disorders
Current Molecular Pharmacology